| Product Name | MF | CAS | Details |
|---|
| Antileishmanial agent-17 | 2934738-40-4 | Details |
| TRK-IN-23 | 2924344-29-4 | Details |
| HIV-1 inhibitor-56 | 2952530-45-7 | Details |
| TNF-α-IN-10 | 2247720-56-3 | Details |
| SLMP53-2 | C26H22N2O2 | 1826116-38-4 | Details |
| Lp-PLA2-IN-12 | 2637485-14-2 | Details |
| Lp-PLA2-IN-15 | C22H17F5N4O3 | 1865796-11-7 | Details |
| CXCR4-IN-1 | 2304750-48-7 | Details |
| PCSK9-IN-17 | 2455424-72-1 | Details |
| HPK1 antagonist-1 | C28H29FN6O2 | 2628489-56-3 | Details |
| RIP1 kinase inhibitor 6 | 2428401-62-9 | Details |
| RIP1 kinase inhibitor 7 | 2428401-23-2 | Details |
| Bromodomain inhibitor-12 (edisylate) | 2010124-27-1 | Details |
| Bromodomain inhibitor-12 | 2010124-06-6 | Details |
| ATR-IN-24 | C23H26N6O2 | 2370889-43-1 | Details |
| MEK-IN-6 | C18H20FN3O4S | 2845151-86-0 | Details |
| RIP1 kinase inhibitor 4 | 2919836-00-1 | Details |
| Lp-PLA2-IN-16 | C22H17F5N4O3 | 1865780-73-9 | Details |
| MEK-IN-6 hydrate | 2845153-35-5 | Details |
| THRβ receptor agonist-1 | 2403721-00-4 | Details |
| Mcl-1 inhibitor 13 | 2445466-06-6 | Details |
| A1/A3 AR antagonist 3 | C22H19N5O3 | 2665804-57-7 | Details |
| P2X3 antagonist 38 | 2545974-71-6 | Details |
| DGKζ-IN-1 | C27H25F3N6O2S | 2660218-70-0 | Details |
| PHD2-IN-1 | 2768219-28-7 | Details |
| ETAP | 2575731-47-2 | Details |
| JAK-IN-30 | 2891469-99-9 | Details |
| AMPK activator 11 | 2948304-00-3 | Details |
| Mosnodenvir | 2890688-86-3 | Details |
| SOS1-IN-16 | 2930763-85-0 | Details |
| PIKfyve-IN-2 | 2245319-25-7 | Details |
| URAT1&XO inhibitor 1 | C20H13N5O3S | 2669726-78-5 | Details |
| PI3Kγ inhibitor 7 | 2575863-25-9 | Details |
| KAT modulator-1 | C20H36O2 | 1314006-43-3 | Details |
| BET-IN-15 | C21H18F2N4O3S | 2408994-22-7 | Details |
| BBDDL2059 | 2691174-27-1 | Details |
| DSO-5a | 2195411-63-1 | Details |
| FKBP51F67V-selective antagonist Ligand2 | 1680228-76-5 | Details |
| K-80001 | 242800-40-4 | Details |
| Bivamelagon hydrochloride | C35H54Cl2N4O4 | 2641595-55-1 | Details |
| ALK/EGFR-IN-1 | 2730430-08-5 | Details |
| RET-IN-23 | C28H28FN11 | 2479961-46-9 | Details |
| STAT6-IN-3 | C32H35IN3O7P | 371919-80-1 | Details |
| UPCDC30766 | 2152623-68-0 | Details |
| Antitubercular agent-39 | 1357796-08-7 | Details |
| MmpL3-IN-2 | 2944458-65-3 | Details |
| Tubulin polymerization-IN-42 | 2640220-51-3 | Details |
| BChE-IN-17 | C23H23BrN2O4S2 | 2425632-57-9 | Details |
| DRI-C21041 | C30H21N3O7S | 2101765-78-8 | Details |
| SARS-CoV-2-IN-57 | 1265624-68-7 | Details |
| Anticancer agent 147 | 2241283-11-2 | Details |
| BDM91514 | 2892824-90-5 | Details |
| Antiproliferative agent-34 | 2910858-34-1 | Details |
| FD2056 | 2685870-87-3 | Details |
| Antiproliferative agent-30 | 2713553-88-7 | Details |
| IRAK4-IN-28 | 2952532-92-0 | Details |
| PAD4-IN-2 | 2642327-52-2 | Details |
| Antitumor agent-101 | 2848632-52-8 | Details |
| FGFR-IN-11 | 2658488-68-5 | Details |
| URAT1&XO inhibitor 2 | C14H12BrNO3 | 1239488-96-0 | Details |
| TLR8 agonist 6 | C19H29N7O2 | 2616605-55-9 | Details |
| PROTAC α-synuclein degrader 5 | C39H41N7O10 | 2781922-42-5 | Details |
| SUCNR1-IN-1 | C26H22ClF3N2O4 | 2711753-52-3 | Details |
| CDK7-IN-22 | C22H25F3N6 | 2173190-60-6 | Details |
| JAK-IN-28 | 2445500-22-9 | Details |
| Protein kinase inhibitor 5 | C29H31F2N7O | 2278204-94-5 | Details |
| SOS1/KRAS-IN-1 | 2836330-34-6 | Details |
| DRI-C25441 | C31H21N3O6 | 2101765-83-5 | Details |
| SORT-PGRN interaction inhibitor 3 | C15H19Cl2NO3 | 2691846-87-2 | Details |
| IRE1α kinase-IN-9 | 1338933-30-4 | Details |
| SHP2-IN-14 | 2673400-91-2 | Details |
| Tau protein aggregation-IN-1 | C17H11BrN2O2 | 916179-45-8 | Details |
| Z1078601926 | C14H19FN2O | 1493256-85-1 | Details |
| VMAT2-IN-2 tosylate | C27H36F3NO6S | 2608770-12-1 | Details |
| ROCK-IN-6 | C19H19N5O8S | 2489328-74-5 | Details |
| Lp-PLA2-IN-14 | 2756855-66-8 | Details |
| IPG7236 | C23H31N3O3S | 2756350-91-9 | Details |
| TLR7/8 agonist 9 | C20H26N6O | 2649170-17-0 | Details |
| Tegeprotafib | C13H11FN2O5S | 2407610-46-0 | Details |
| RIP1 kinase inhibitor 5 | C13H17F2NO2 | 2428422-17-5 | Details |
| PCSK9-IN-16 | C16H20N6O2S3 | 2455424-51-6 | Details |
| TLR7/8 agonist 8 | C24H30N6O | 2649170-16-9 | Details |
| Lp-PLA2-IN-13 | C22H17F5N4O4 | 2756855-62-4 | Details |
| MDM2/XIAP-IN-2 | C29H32N2O4S | 2761969-85-9 | Details |
| AMPA receptor modulator-4 | C11H12ClFN2O2S | 2917551-59-6 | Details |
| ALK2-IN-5 | C24H32N8O2 | 2414149-20-3 | Details |
| Antibacterial agent 141 | 2930013-56-0 | Details |
| HDAC ligand-1 | C7H8N2O | 34840-28-3 | Details |
| PB131 | C16H16FN3O2 | 2924425-63-6 | Details |
| Antileishmanial agent-16 | 2934738-41-5 | Details |
| Antiproliferative agent-32 | 2925814-05-5 | Details |
| MAT2A-IN-12 | C20H17NO3 | 631897-75-1 | Details |
| S-Gem | C13H15F2N3O6S2 | 2169925-98-6 | Details |
| Enpp-1-IN-17 | C18H24N4O2 | 2289736-54-3 | Details |
| Bivamelagon | C35H53ClN4O4 | 2641595-54-0 | Details |
| SSI-4 | C19H21ClN4O3 | 1875084-68-6 | Details |
| Antifungal agent 59 | 2422019-96-1 | Details |
| IRE1α kinase-IN-8 | 1338933-29-1 | Details |
| Antileishmanial agent-15 | 2934738-38-0 | Details |
| Product Total： Product Page： | ||||
| 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 | ||||